Drugs / ICVAX
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07530198 | Mar 2026 → Mar 2027 expected | HIV infectious disease | Immuno Cure Holding (HK) Limited | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ICVAX | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07530198 ↗ |
| Modality | Vaccine | “HIV Therapeutic DNA Vaccine (ICVAX)” NCT07530198 ↗ |
| Route | Intramuscular | “ICVAX will be administered intramuscularly followed by electroporation using the TERESA-EPT I device.” NCT07530198 ↗ |